Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
IDEAYA Biosciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant must be at least 18 years of age
Advanced or metastatic solid tumor that has progressed on at least one prior line of treatment or is intolerant to additional effective standard therapy
Have evidence of homozygous loss of MTAP or MTAP deletion
Willing to undergo paired fresh biopsy (pre- and post-treatment) procedure. Exceptions may be made for feasibility and safety concerns
Measurable disease
ECOG performance status \<= 1
Adequate organ function
Able to swallow and retain orally administered study treatment
Recovery from acute effects of prior therapy
Able to comply with contraceptive/barrier requirements
You may not be if
Known symptomatic brain metastases
Known primary CNS malignancy
Current active liver or biliary disease
Impairment of gastrointestinal (GI) function
Active uncontrolled infection
Clinically significant cardiac abnormalities
Active second malignancy or history of another malignancy in the past 2 years
Previous treatment with a MAT2A inhibitor and / or PRMT inhibitor or sacituzumab govitecan
Systemic anti-cancer therapy, therapeutic antibody treatment, or major surgery within 4 weeks prior to study entry
Current radiation-related toxicity or radiation therapy within 2 weeks prior to study entry
Small molecule anti-cancer treatment within 2 weeks prior to study entry
Prior irradiation to \>25% of the bone marrow
Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers
Require concomitant use of proton pump inhibitor
Currently receiving another investigational study drug.
Known or suspected hypersensitivity to IDE397/excipients or components
Clareo Health | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
